Showing 1,021 - 1,040 results of 104,576 for search '(( a fold decrease ) OR ( 5 ((((nn decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.53s Refine Results
  1. 1021
  2. 1022
  3. 1023
  4. 1024

    Diagnostic performance of blood parameters to discriminate abnormal from normal MAD activity (A) and decreased from absent MAD activity (B). by Fabrice Rannou (775170)

    Published 2015
    “…(B) Classifiers for the differentiation of Absent (n = 5) from Decreased (n = 6) MAD activity. 50% PMP: 50% from predicted maximal power (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132972#sec006" target="_blank">Methods</a>), R: Recovery from exercise, Se: Sensibility, Sp: Specificity, Acc: Accuracy, PPV: Positive predictive value, NPV: Negative predictive value, LR+: Positive likelihood ratio, LR-: Negative likelihood ratio, DOR: Diagnostic odds ratio, NC: Not calculable.…”
  5. 1025

    The 10 most highly regulated genes in sputum and blood from microarray analysis; a positive fold change  =  increase in frequent exacerbators compared to zero exacerbators, a negative fold change  =  decrease in frequent exacerbators compared to zero exacerbators. by Dave Singh (114223)

    Published 2014
    “…</p><p>The 10 most highly regulated genes in sputum and blood from microarray analysis; a positive fold change  =  increase in frequent exacerbators compared to zero exacerbators, a negative fold change  =  decrease in frequent exacerbators compared to zero exacerbators.…”
  6. 1026
  7. 1027

    GFP activity is decreased in DES. by Céline Portal (3876436)

    Published 2017
    “…AB—PAS and serial immunohistochemical section of the left eye, which received PBS, and paired-right eye which received BAK show a decrease in the number of conjunctival goblet cells producing Muc5b (blue arrows) and non-Muc5b producing (white arrows) cells. …”
  8. 1028
  9. 1029
  10. 1030
  11. 1031

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…Compound <b>4f</b> exhibited potent EGFR inhibitory activity with an IC<sub>50</sub> value of 61 nM compared to that of Tamoxifen (IC<sub>50</sub> value of 69 nM), with EGFR inhibition of 83 and 84%, respectively, at a concentration of 10 μM. Interestingly, <b>4f</b> showed remarkable PI3K/AKT/mTOR inhibitory activity with 0.18-, 0.27-, and 0.39-fold decrease in their concentration (reduction in controls from 6.64, 45.39, and 86.39 ng/mL to 1.24, 12.35, and 34.36 ng/mL, respectively). …”
  12. 1032

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…Compound <b>4f</b> exhibited potent EGFR inhibitory activity with an IC<sub>50</sub> value of 61 nM compared to that of Tamoxifen (IC<sub>50</sub> value of 69 nM), with EGFR inhibition of 83 and 84%, respectively, at a concentration of 10 μM. Interestingly, <b>4f</b> showed remarkable PI3K/AKT/mTOR inhibitory activity with 0.18-, 0.27-, and 0.39-fold decrease in their concentration (reduction in controls from 6.64, 45.39, and 86.39 ng/mL to 1.24, 12.35, and 34.36 ng/mL, respectively). …”
  13. 1033
  14. 1034
  15. 1035
  16. 1036
  17. 1037
  18. 1038
  19. 1039
  20. 1040